focus -WSS

focus

author：hotspot 2025-09-27 22:05:51 - browse：68

Pfizer and Moderna aren’t the only vaccine money-makers. Much of the revenue and profits from Covid-19 vaccines are flowing behind the scenes, going to the contract manufacturers and clinical-trial organizers that turn the shots from lab-bench theory to mass-produced reality.

Both AstraZeneca and Johnson & Johnson publicly committed to not profiting off their products during the pandemic — though AstraZeneca has reserved the right to declare the pandemic over on July 1, even if the World Health Organization has not. Pfizer and Moderna made no such pledge, with Pfizer expected to make $15 billion in vaccine-related revenue this year, while Moderna is forecasting $18.4 billion in vaccine sales.

Contractors hired to test and manufacture these vaccines have enjoyed a share of the profits without the same level of public scrutiny.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： NIH nominee Bertagnolli will get October confirmation hearing

knowledge

WSS

Trump surgeon general acknowledges mistakes during Covid

How to fix cancer clinical trials' diversity problem

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Are embryos people? Reproductive medicine's future depends on the answer

Color Health wants to make cancer screenings convenient

Childhood vaccination ad campaign launches in the U.K.

knowledge

focus

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

STAT Madness 2024: Meet the contenders

Activists slam private health insurers over coverage restrictions

What American doctors can learn from their Israeli counterparts

Guidelines to prevent youth baseball injuries need more muscle

CDC advisory group OKs chikungunya vaccine

Drug repurposing or repositioning? The language matters

NIH nominee Bertagnolli will get October confirmation hearing

New air purifier tech could be key to improving indoor air quality

Illumina names Agilent executive as new CEO

focus

Readout Newsletter: Beam, Prozac, "TechBio" and more

Medicare Advantage isn’t working — for anyone

How to fix cancer clinical trials' diversity problem

AstraZeneca chief proposes a novel edit to the drug pricing bill

Medicare isn't yet testing food as medicine

Childhood vaccination ad campaign launches in the U.K.

entertainment

knowledge

leisure time

hotspot